Next Article in Journal
Follow-Up of Patients Who Are Clinically Disease-Free after Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation
Previous Article in Journal
Patterns of Practice with Third-Line Anti-EGFR Antibody for Metastatic Colorectal Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 5
10.3747/co.23.3205
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level

by
D.J. Kagedan
1,*,
M.E. Dixon
2,
R.S. Raju
3,
Q. Li
4,
M. Elmi
1,
E. Shin
5,
N. Liu
4,
A. El-Sedfy
6,
L. Paszat
3,4,5,
A. Kiss
3,4,7,
C.C. Earle
3,4,5,
N. Mittmann
8 and
N.G. Coburn
1,3,4,5,7
1
Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON M4N 3M5, Canada
2
Department of Surgery, Maimonides Medical Center, Brooklyn, NY, USA
3
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4
Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
5
Faculty of Medicine, University of Toronto, Toronto, ON, Canada
6
Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA
7
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
8
Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Research Institute, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(5), 334-342; https://doi.org/10.3747/co.23.3205
Submission received: 3 July 2016 / Revised: 7 August 2016 / Accepted: 6 September 2016 / Published: 1 October 2016

Abstract

Background: In the present study, we aimed to describe, at the population level, patterns of adjuvant treatment use after curative-intent resection for pancreatic adenocarcinoma (PCC) and to identify independent predictors of adjuvant treatment use. Methods: In this observational cohort study, patients undergoing PCC resection in the province of Ontario (population 13 million) during 2005–2010 were identified using the provincial cancer registry and were linked to administrative databases that include all treatments received and outcomes experienced in the province. Patients were defined as having received chemotherapy (CTX), chemoradiation (CRT), or observation (OBS). Clinicopathologic factors associated with the use of CTX, CRT, or OBS were identified by chi-square test. Logistic regression analyses were used to identify independent predictors of adjuvant treatment versus OBS, and CTX versus CRT. Results: Of the 397 patients included, 75.3% received adjuvant treatment (27.2% CRT, 48.1% CTX) and 24.7% received obs. Within a single-payer health care system with universal coverage of costs for CTX and CRT, substantial variation by geographic region was observed. Although the likelihood of receiving adjuvant treatment increased from 2005 to 2010 (p = 0.002), multivariate analysis revealed widespread variation between the treating hospitals (p = 0.001), and even between high-volume hepatopancreatobiliary hospitals (p = 0.0006). Younger age, positive lymph nodes, and positive surgical resection margins predicted an increased likelihood of receiving adjuvant treatment. Among patients receiving adjuvant treatment, positive margins and a low comorbidity burden were associated with CRT compared with CTX. Conclusions: Interinstitutional medical practice variation contributes significantly to differential patterns in the rate of adjuvant treatment for PCC. Whether such variation is warranted or unwarranted requires further investigation.
Keywords: pancreatic cancer; adjuvant chemotherapy; combined-modality therapy; medical practice variation; population analyses pancreatic cancer; adjuvant chemotherapy; combined-modality therapy; medical practice variation; population analyses

Share and Cite

MDPI and ACS Style

Kagedan, D.J.; Dixon, M.E.; Raju, R.S.; Li, Q.; Elmi, M.; Shin, E.; Liu, N.; El-Sedfy, A.; Paszat, L.; Kiss, A.; et al. Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level. Curr. Oncol. 2016, 23, 334-342. https://doi.org/10.3747/co.23.3205

AMA Style

Kagedan DJ, Dixon ME, Raju RS, Li Q, Elmi M, Shin E, Liu N, El-Sedfy A, Paszat L, Kiss A, et al. Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level. Current Oncology. 2016; 23(5):334-342. https://doi.org/10.3747/co.23.3205

Chicago/Turabian Style

Kagedan, D.J., M.E. Dixon, R.S. Raju, Q. Li, M. Elmi, E. Shin, N. Liu, A. El-Sedfy, L. Paszat, A. Kiss, and et al. 2016. "Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level" Current Oncology 23, no. 5: 334-342. https://doi.org/10.3747/co.23.3205

APA Style

Kagedan, D. J., Dixon, M. E., Raju, R. S., Li, Q., Elmi, M., Shin, E., Liu, N., El-Sedfy, A., Paszat, L., Kiss, A., Earle, C. C., Mittmann, N., & Coburn, N. G. (2016). Predictors of Adjuvant Treatment for Pancreatic Adenocarcinoma at the Population Level. Current Oncology, 23(5), 334-342. https://doi.org/10.3747/co.23.3205

Article Metrics

Back to TopTop